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Introduction 
 
This work reports the results of two different lines of research: 1. On the 
employment of ultrasound in the management of fetuses with intra-uterine growth 
restriction (IUGR); 2. On management of preterm birth for prevention of 
neurological impairment in high-risk pregnancies and low risk pregnancies. Pre-
natal flow data and post-natal neurological outcome in IUGR fetuses have been 
evaluated. Doppler ultrasound in obstetrics has allowed the detection of the early 
signs of fetal demise, involving the management of pregnancies at risk of fetal 
hypoxia. The second line of research focuses on the need to identify strategies to 
predict preterm birth in asymptomatic low-risk women as well as in those 
presenting with threatened preterm labor (symptomatic high risk women) and 
underlines the importance to prevent brain injury and long-term neurologic 
sequelae related to preterm deliveries. 
Neurological insults result in significant immediate and longterm physical, 
emotional, and financial costs. The risks of intraventricular hemorrhage (IVH), 
cerebral palsy (CP), and neurological impairment are closely related to gestational 
age of delivery (1); thus, the timing of delivery for FGR (fetal growth restriction) 
fetuses is crucial as well as the prevention of preterm delivery that are perhaps, the 
most effective strategy for neonatal neuroprotection (2). The major hypoxic-
ischemic lesion of the preterm infant is periventricular leukomalacia (PVL) 
representing injury to the cerebral white matter. Preterm infants thought to be at 
greatest risk for PVL are those born between 23 and 32 weeks’ gestation. PVL is a 
spectrum from the classic focal cystic variety to diffuse noncystic white matter 
injury. Interestingly, PVL with focal macrocysts detectable by sonography has 
declined  and PVL is dominated by the diffuse variety that can be detected by MRI 
but not sonography. The predominant pathology underlying PVL is an arrest in the 
lineage of oligodendrocytes at the pre-oligodendrocyte stage and results in reduced 
brain myelination (3). 
For the extreme preterm infant (<29 weeks’ gestation), the pre-oligodendrocyte 
represents most of the oligodendrocyte population and is extremely sensitive to 
hypoxiaischemia and inflammation, which represent triggers for the initiation of 
white matter injury. 
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However, PVL with microcysts (focal necrosis) is associated with remote neuronal 
loss most commonly in the thalamus, basal ganglia, and cerebellar dentate nucleus 
compared. The involvement of gray matter lesions with diffuse white matter injury 
has prompted the term “encephalopathy of prematurity” (4). 
Intracranial hemorrhage (ICH) may also represent a hypoxic-ischemic injury 
occurring primarily in extreme preterm infants (<29 weeks’ gestation).  In clinical 
practice, the terms hypoxia-ischemia and asphyxia are often used interchangeably. 
Technically there are important differences. Hypoxia is a low content of oxygen in 
the blood, whereas ischemia represents a reduction in tissue blood flow. Ischemia 
in turn can be partial or complete in extent, and can be focal or global in 
distribution; hypoxia and ischemia are often combined because each component 
may result in the other. In contrast, asphyxia indicates an impairment of gas 
exchange and is characterized by anoxia and extremes of hypercarbia. 
ICH is a hemorrhagic lesion initiated in the periventricular germinal matrix; 
deranged cerebral hemodynamics may contribute to ICH.  
Because it is difficult to identify hypoxia-ischemia/asphyxia among preterm 
infants at or soon after birth, studies that examined the incidence of these events 
have focused on more mature gestational ages. Salhab and Perlman reported 
moderate and severe encephalopathy among infants 31 to 36 weeks’ gestation with 
severe fetal acidemia; the incidence of encephalopathy was 1.4 per 1000 live 
births. There are no available data for the incidence of hypoxia-ischemia/asphyxia 
among extreme preterm infants. (4). 
In the IUGR infant, brain injury may be due to a combination of grey matter and 
white matter disruption and disorganisation in the development of the brain. 
Clinical imaging studies of preterm IUGR infants have demonstrated significant 
alterations in white and grey matter volume and structure including decreased 
cortical thickness, delayed cortical development and altered brain connectivity in 
comparison to non-IUGR preterm infants. Reduced cerebral cortical grey matter 
volume in the term IUGR neonate has been shown to correlate with attention 
disorders  (5
a
). A four-to sixfold increase in CP has been shown in IUGR neonates; 
the IUGR fetus is relatively hypoxic due to chronic placental oxygen deprivation. 
The chronic IUGR insult leads to a reduction in oxygen delivery to the brain and 
concomitant reduction in delivery of glucose and aminoacids with potential effects 
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on immature neurons and neuroglia (5
b
). When cerebral oxygen is reduced, a 
cascade of cellular and biochemical events occurs in the fetal brain causing cellular 
injury that can lead to cell death. Many of these events result in mitochondrial 
disruption and immediate or delayed cell death (5
b
). The major putative 
mechanisms that may underpin the cellular death and injury in IUGR brains are 
excitotoxicity, oxidative stress, necrotic and apoptotic degeneration and 
neuroinflammation. 
On the other hand, advances in obstetrical and neonatal care have led to survival at 
earlier gestational ages and consequently increasing numbers of periviable infants 
who are at significant risk for long-term neurological deficits. Therefore, efforts to 
decrease and prevent cerebral insults attempt not only to improve neurological 
outcomes in infants delivered preterm but also primarily to decrease preterm 
delivery. 
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I Research line : Fetal and perinatal surveillance of brain injury 
  
Human brain development is a protracted process that begins in the third 
gestational week (GW) with the differentiation of the neural progenitor cells and 
extends at least through late adolescence, arguably throughout the lifespan (6). The 
nine months of intrauterine life are a continuum during which a series of situations 
and events can occur that result in abnormalities of normal brain growth or injury 
to the developing brain of the fetus. During this time there is rapid growth and 
elaboration of both cortical and subcortical structures, including the rudiments of 
the major fiber pathways. 
Both gene expression and environmental input are essential for normal brain 
development, and disruption of either can fundamentally alter neural outcomes. 
By the end of the embryonic period the rudimentary structures of the brain and 
central nervous system are established and the major compartments of the central 
and peripheral nervous systems are defined. The early fetal period, which extends 
to approximately midgestation, is a critical period in the development of the 
neocortex. Most cortical neurons are generated by that time and many have 
migrated to their positions in the neocortex and have begun to from essential brain 
networks for information processing (7). Different pathogenic noxae can damage 
cerebral tissues in a variety of different ways. The damage that results from a 
systemic condition of hypoxia / acidosis or from a local ischemic condition is 
certainly a major cause of perinatal morbidity and mortality. The pattern and 
consequences of injury depend on the severity and duration of the insult; the 
neurovascular and anatomical maturity of the brain is primarily a factor related to 
the gestational age of the fetus, and co-related factors such as the presence or 
absence of infection or problems with fetal nutrition (8). Hypoxia is central to the 
genesis of a significant proportion of the brain injury that occurs in the fetus; but 
the fetus is at risk of brain injury whenever cerebral ischemia occurs as a 
consequence of impaired cerebral blood flow. It is estimated that the incidence of 
encephalopathy due to intrapartum asphyxia alone (in the absence of other possible 
causes antepartum) is 1.6 per 10,000 births (3-20% of all the cerebral palsy); 
prematurity and infections during pregnancy, however, represent the most 
common causes of cerebral palsy compared to intrapartum events. 
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The condition predisposing the neurological damage is cerebral edema; cellular 
edema is defined as the premorbid cellular process, known as oncotic cell swelling, 
whereby extracellular Na+ and other cations enter into neurons and astrocytes and 
accumulate intracellularly, in part due to failure of energy-dependent mechanisms 
of extrusion. Cells in both gray and white matter are affected initially by cytotoxic 
edema. Cellular swelling begins within 30 minutes of MCA occlusion, particularly 
around capillaries, persists for up to 24 hours after reperfusion, and results in an 
average reduction of extracellular space from the normal 20% down to 4 to 10% 
(9
a
). The cerebral vascular system has anatomical and physiological barriers that 
regulate the transfer of compounds into the brain; a damage of this barrier causes a 
vasogenic cerebral edema, in which extracellular water and other substances passes 
into cells, resulting in their swelling.  
The special autoregulation of fetal cerebral circulation, with more sprayed brain 
territories during intrauterine life (different Doppler indices) and the physiological 
subcortical hypoperfusion in fetuses, is a sort of functional reserve of the fetal 
brain in extreme response to hypoxia. 
The concomitant involvement of the cerebral cortex, basal ganglia, thalamus, brain 
stem and the cerebellum has been associated with poor neurodevelopmental 
outcome. 
Premature neonates who are also of a low birth weight are at the highest risk of 
periventricular leukomalacia (PVL) and germinal matrix-intraventricular 
hemorrhage (GM-IVH).  PVL is characterized by hemorrhagic necrosis of the 
white matter surrounding the lateral ventricles. It can be diffuse or focal and 
commonly occurs in the preterm infant. This “selective vulnerability” (9b) governs 
the subsequent manifestation of injury. Blood vessels within the germinal matrix 
are fragile, particularly during the period of high cell turnover (24–32 weeks 
gestation) associated with corticogenesis. IVH implies structural immaturity of 
blood vessels in the germinal matrix, and is associated with deficient 
autoregulatory capacity and pressure-passive cerebral perfusion.  
The impact of early brain insults depends both on the timing and on the exent of 
the damage; the developing brain is capable of reorganizing to compensate for 
injury by creating novel neuronal networs.  
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So the IUGR fetuses are at risk of intraventricular hemorrhage, because they are 
often preterm fetuses. 
Intrauterine growth restriction (IUGR) refers to a condition in which a fetus is 
unable to achieve its genetically determined potential size. This functional 
definition seeks to identify a population of fetuses at risk for modifiable but 
otherwise poor outcomes. This definition intentionally excludes of fetuses that are 
small for gestational age (SGA) but are not pathologically small. SGA is defined 
as growth at the 10th percentile for weight of all fetuses at that gestational age. Not 
all fetuses that are SGA are pathologically growth restricted and, in fact, may be 
constitutionally small. Similarly, not all fetuses that have not met their genetic 
growth potential are in less than the 10th percentile for estimated fetal weight 
(EFW).  
The American College of Obstetricians and Gynecologists (ACOG) defines FGR 
as an estimated fetal weight less than the 10th centile (10). The Royal College of 
Obstetricians and Gynaecologists (RCOG) uses fetal abdominal circumference 
(AC) or estimated fetal weight (EFW) <10th centile to diagnose a FGR fetus (11). 
Other authors have suggested, as definition of fetal growth restriction, a 
combination of fetal smallness and umbilical artery Doppler PI >95th percentile 
(12, 13). 
Hovewer, FGR shouldbe referred to fetuses with pathological smallness caused by 
an underlying functional problem and hence a definition including not only a 
biometric cut off but also Doppler indices of feto-placental function is currently 
agreed in most Fetal Medicine Units (12,13, 14). 
These fetuses are at risk of developing lifelong disabilities, such as asphyxia, 
meconium aspiration, haematological disorders and cerebral palsy. Some studies 
also report an association with several major in adulthood diseases: coronary heart 
disease, hypertension and type 2 diabetes (15). 
Placental insufficiency is the leading cause of FGR and is usually due to poor 
uteroplacental blood flow and placental infarcts. The reduction of placental supply 
of nutrients to the fetus has been associated with several adaptive changes taking 
place in both the placenta and fetus.  
Despite numerous approaches to managing FGR, there are no effective treatments 
to improve the growth pattern of a fetus; howewer  prenatal management is aimed 
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primarily at determining the ideal timing and mode of delivery. This assessment 
must be individualised, depending on several variables: gestational age of the 
fetus, maternal health, severity of growth restriction and fetal well‐being. Perhaps 
optimising the delivery time and removing the fetus from a suboptimal 
environment can prevent the risk of hypoxia and major neurological morbidities 
(16).  
A prerequisite for a correct diagnosis of FGR is accurate dating of the pregnancy, 
most usually in the first trimester. An accurate prenatal differentiation between 
FGR and SGA is challenging. Although size is a physical parameter that can be 
measured at any gestational age, growth is a dynamic process that can be assessed 
only by repeated measurements; and sequential assessments are necessary to 
determine whether there is a decrease in the fetal growth rate.  
In other words, the term SGA refers to the size, irrespective of the growth velocity 
in the uterus e these are usually associated with normal placental function and have 
a normal outcome; FGR is SGA in which circulatory redistribution occurs so that 
the brain is preferentially perfused and there is a abnormal umbilical artery with 
pulsatility index above the 95th percentile. 
Birth weight alone is no longer considered the key factor, as it poorly reflects 
intrauterine events and depends on several factors unrelated to developmental 
programming. Fetal size charts are used to compare the size of a fetus (of known 
gestational age) with reference data and to compare it on two or more different 
circumstances; there are several growth charts, but they are very heterogeneous 
between them.  
FGR may also be classified by gestational age at onset as early and late, with an 
arbitrary cut-off conventionally set at 32 weeks: the extremes of the clinical 
spectrum of FGR differ not only for gestation at onset, but also for clinical 
manifestations, patterns of fetal deterioration, association with hypertensive 
disorders of the pregnancy and severity of placental dysfunction (17, 18). Fetuses 
with late-onset disease do not present the same sequence of Doppler deterioration 
described for early-onset FGR (13). Early-onset FGR is associated with high 
impedance utero placental perfusion which in turn leads to elevated umbilical 
artery blood flow resistance once villous damage exceeds 30%; late-onset FGR is 
more common but less severe with absent or mild placental abnormalities; 
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umbilical artery Doppler may be normal, but fetuses may react with decreased 
middle cerebral artery (MCA) impedance in response to hypoxemia (19).  
The ultrasound examination with Doppler investigation is of great help in the 
diagnosis and follow-up with IUGR fetuses and in the assessment of a possible 
brain injury. 
The clinical efficacy of umbilical artery Doppler velocimetry in these fetuses 
IUGR is validated by different randomized studies and, in clinical practice, led to a 
29% reduction in perinatal mortality. 
The umbilical artery, middle cerebral artery, ductus venosus and uterine artery 
provide a comprehensive evaluation. 
Physiological modification of spiral arteries is required to permit the ten-fold 
increase in uterine blood flow which is necessary to meet the respiratory and 
nutritional requirements of the fetus and placenta; impaired trophoblastic invasion 
of the maternal spiral arteries is associated with increased risk for subsequent 
development of obstetric complications related to uteroplacental insufficiency. 
Increased impedance to flow in the uterine arteries in a one-stage color Doppler 
screening program at 23 weeks can detect a fetus at higher risk of serious 
complications of impaired placentation and  growth restriction and subsequently 
adverse perinatal outcome. However, this screening test for risk is not an 
assessment of fetal well-being and has no established place in the management of 
infants diagnosed with FGR (20).  
Umbilical artery Doppler is the only measure that provides both diagnostic and 
prognostic information for the management of FGR (21);  umbilical  artery  should  
not be used as a screening tool in healthy pregnancies, as it has not been shown to 
be of value in this group (22). In terms of monitoring growth-restricted 
pregnancies, abnormal waveforms in the umbilical artery are an early sign of fetal 
impairment. With advancing gestation, umbilical arterial Doppler waveforms 
demonstrate a progressive rise in the end-diastolic velocity and a decrease in the 
impedance indices. In the presence of placental insufficiency with progressive 
severity, there is a higher placental resistance, indicated by a high pulsatility index, 
absent or reversed end-diastolic component of the umbilical artery waveform. 
Different studies have demonstrated that increased impedance in the umbilical 
arteries becomes evident only when at least 60% of the placental vascular bed is 
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obliterated. In pregnancies with reversed or absent end diastolic frequencies in the 
umbilical artery, mean placental weight is reduced and the cross-sectional diameter 
of terminal villi is shorter. In addition, significantly more these neonates needed 
admittance to the neonatal intensive care unit and they had a higher risk of cerebral 
hemorrhage, anemia or hypoglycemia and increased incidence of long-term 
permanent neurological damage.  
At the lower limits of oxygen availability there is an increase in the blood supply 
to the brain, myocardium and the adrenal glands and reduction in the perfusion of 
the kidneys, gastrointestinal tract and the lower extremities.  
The middle cerabral artery (MCA) is the vessel of the choice to assess the fetal 
cerabral circulation because it is easy to identify, has a high reproducibility, and 
provides an information about the brain sparing effect. Additionaly, it can be 
studied easily with an angle of zero degrees between an ultrasound beam and the 
direction of blood flow and, therefore, information on true velocity of the blood 
flow can be obtained. The MCA is the largest branch of the circle of Willis and it 
represents the lateral continuation of the internal carotid artery (ICA) into the 
Sylvian fissure. It has the largest volume of flow of all the vascular branches 
arising from the circle of Willis, carrying about 80% of the flow to the hemisphere. 
It consists of four segments: M1 (at the origin- optical chyasma), M2 (the distal 
tract- the extreme wings of large sfenoid), M3 and M4 (this segment runs 
temporally and frontally); M1 and M2 supply different parts of the fetal brain, 
which develop in different periods of fetal life (23), with statistically significant 
differences between 26 weeks and 36 weeks. 
To maintain cerebral homeostasis, there are specialized mechanisms mediate the 
short-term vasodilatory responses to acute hypoxia and more long-term changes in 
artery structure and reactivity enable the fetus to adapt to chronic hypoxia. 
A condition of chronic hypoxia determines a fetal flow redistribution that 
manifests as vasodilatation in the brain circulation. Cerebral vasodilatation, easily 
detectable as a reduction in the PI of the middle cerebral artery (MCA) represents 
an adaptative mechanism in response to hypoxia; blood flow is centralized and the 
Brain Sparing Effect appears to be a benign adaptive mechanism preventing severe 
brain damage (24).  
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However, compensation through cerebral vasodilatation is limited and a plateau 
corresponding to a nadir of pulsatility index (PI) in cerebral vessels is reached 
before the development of the fetus is impaired. In late-onset IUGR, there is 
observational evidence that MCA vasodilatation is associated with adverse 
outcome independently of the umbilical artery. This suggests a role of MCA 
Doppler for fetal monitoring in late-onset IUGR cases, which needs further 
investigation in randomized trials (25).  
In recent years it has increased the interest for the Cerebroplacental ratio (CPR), 
that quantifies the redistribution of cardiac output by dividing the Doppler indices 
of the middle cerebral artery (MCA) with that of the umbilical artery. J. Morales-
Rosello et al. in their study suggest that low CPR in AGA fetuses is an equally 
important marker of low neonatal pH secondary to placental underperfusion and  
this finding may be of value in risk assessment for stillbirth at term and long-term 
neurodevelopmental disability (26). Of note, the PORTO study demonstrated the 
association between redistribution, either isolated or associated with umbilical 
artery PI >95th centile, and adverse perinatal outcome (27). Thus, a reduction of 
the MCA PI and the relationship between MCA PI and UA PI CPR is an early sign 
of hypoxia in IUGR fetuses and it is associated with a high risk of brain damage as 
well as ischemia and cerebral hemorrhage. The finding of a centralization of 
circulation confirms a state of fetal hypoxia and the need of the study of fetal 
venous circulation to highlight the deterioration of heart function with 
cardiovascular changes that can be shown by venous Doppler studies. 
The ductus venosus plays a central role in the return of venous blood from the 
placenta. Well-oxygenated blood flows via this shunt directly towards the heart. 
Early studies on IUGR fetuses demonstrated a good correlation of abnormal DV 
waveform with acidemia at cordocentesis and this Doppler sign is considered a 
surrogate parameter of the fetal base-acid status. Of note longitudinal studies have 
demonstrated that DV flow waveforms become abnormal only in advanced stages 
of fetal compromise (28).  
All these types of velocimetry evaluations have contributed to the understanding of 
metabolic and vascular events underlying the hypoxic-ischemic brain.  
IUGR is one of the most common pregnancy complications and substantially 
increases the prospective risk of adverse outcome. Yet according to pregnancy 
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audits, most instances of IUGR are not detected as such antenatally. Modern 
obstetric care needs to raise the level of awareness of the importance of this 
condition, and establish evidence-based protocols for improved surveillance. At 
present there is no effective intervention for FGR except delivery and importantly, 
gestational age is the most significant determinant of both survival and intact 
survival. Thus, the main consideration needs to be appropriate timing, balancing 
the risk of potential iatrogenic morbidity and continued exposure to an unfavorable 
intrauterine environment. 
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Objective 
 
To determine the relationship between prenatal parameters, sonographic and not, 
with  neonatal outcome in pregnancies with IUGR fetuses, it began this research 
project, that was held in  two different time. 
The aim of first research article has been to evaluate the expression of some non 
collagenous extracellular matrix proteins, in particular tenascin, in human 
placentas of intrauterine growth restricted fetuses with abnormal umbilical 
Doppler velocimetry.  The presence of tenascin might be considered as a placental 
compensatory mechanism in FGR fetuses with abnormal umbilical artery Doppler 
velocimetry.  
Then the second study has realized an intensive prenatal and postnatal monitoring 
in IUGR fetuses, in order to correlate fetal Doppler with  neurological outcome. 
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Tenascin Expression in Human Placentas during FGR Affected 
Pregnancies and Umbilical Doppler Velocimetry Correlation 
 
Abstract 
Objective: The aim of this study was to evaluate the expression of some non 
collagenous extracellular matrix proteins, in particular tenascin, in human 
placentas of intrauterine growth restricted fetuses with abnormal umbilical 
Doppler velocimetry.  
Study Design: Study group (group A) consisted of 23 pregnant women with 
intrauterine growth restricted fetuses, with or without preeclampsia. Control group 
(group B) consisted of 10 pregnant women with appropriate fetal weight for 
gestational age. Placental specimens were collected from biopsies obtained after 
cesarean delivery. Umbilical artery Doppler velocimetry was performed within 
four hours from delivery in all patients. Tenascin expression was studied by 
immunohistochemistry and western blot techniques.  
Results: A difference in birth weight and placental weight was found in the two 
groups, being lower in the study group. Umbilical artery Doppler velocimetry 
showed abnormal patterns in the study group and normal findings in the control 
one. Tenascin was strongly expressed in placentas from growth restricted fetuses, 
as shown by immunohistochemistry and by RT-PCR, while it was almost absent in 
placentas from group B. 
Conclusion: A relationship between abnormal Doppler patterns and tenascin 
distribution in growth restricted fetuses has been observed. The presence of 
tenascin might be considered as a placental compensatory mechanism in FGR 
fetuses with abnormal umbilical artery Doppler velocimetry. 
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Introduction 
Fetal Growth Restricted (FGR) fetuses are the fetuses in which growth restriction 
implies a pathological restriction of the genetic growth potential. As a result, FGR 
fetuses manifest evidence of fetal compromise i.e. abnormal Doppler velocimetry 
[1]. FGR with or without Preeclampsia (PE) complicates a significant number of 
pregnancies [2,3]. This condition is an important risk factor for adverse perinatal 
outcome and contributes to maternal and perinatal morbidity and mortality. 
Impaired placental perfusion and angiogenesis seem to be the most common 
causes of FGR, even if, in some cases, both FGR and PE are related to a failure of 
immunomodulatory placental functions [4,5]. Moreover, excessive levels of 
placental oxidative stress lead to PE and FGR, and placental hypoxia-
reoxygenation is a potential cause of such stress. High levels of Reactive Oxygen 
Species (ROS) may induce cellular apoptosis. Thus, ROS-scavenging enzymes, 
such as Superoxide Dismutase (SOD) enzyme family, are important for preserving 
fetal growth [6]. 
Several placental histological and morphological abnormalities such as infarcts, 
terminal villous fibrosis and impaired trophoblastic invasion have been well 
described in FGR placentas [7-10]. Many studies have reported an association 
between abnormal Doppler velocimetry changes in umbilical artery and adverse 
perinatal outcome in growth restricted fetuses. The correlation between placental 
morphology and umbilical artery Doppler velocimetry, an indicator of placental 
vascular resistance, shows that substantial changes in the growth of villi and in 
fetal vasculature can reduce maternal-fetal exchanges of nutrients and oxygen and 
contribute to fetal hypoxic stress [11]. 
The human placenta, as a boundary organ between mother and fetus, plays a 
dynamic role in establishing and maintaining pregnancy through a multifunctional 
way involving continuous rearrangement in its structure. It is now widely accepted 
that the Extracellular Matrix (ECM) is a dynamic and highly specialized structure, 
involved in several signal transduction pathways [12]. For instance, ECM proteins 
are degraded by Matrix Metalloproteinases (MMPs), endopeptidase capable of 
processing a number of bioactive molecules. They are released by placental cells 
during tissue remodeling processes, cell migration and neoangiogenesis: 
aberrations in MMPs activity in  early pregnancy can play a role in the 
18 
 
physiopathology of conditions like FGR [13]. It has been recently suggested that 
ECM proteins, such as fibronectin, tenascin and laminin, play different roles in cell 
proliferation, migration and differentiation. Tenascin, in particular, has shown to 
be able in modulating cellular adhesion by increasing or decreasing it, and seems 
to be involved in the immunological protection of the embryo during implantation. 
Moreover, tenascin seems to be involved in villous repairing after placental 
infarctions and in neoangiogenic mechanisms [14,15]. Also fibronectin, which 
often co-distributes with tenascin, and laminin, can induce migration of cell 
populations and metabolites [16]. Cell–matrix interactions represent a so important 
phenomenon that we can hypothesize that some changes in the structure and in the 
distribution of these proteins are involved in pregnancies complicated by FGR. 
Moreover, tenascin, whose expression has been correlated with villous growth, 
cells proliferation and fibrinoid deposition, may play a critical role in placental 
homeostasis development throughout pregnancy [14]. 
Tenascin is a large ECM glycoprotein. Until now five isoforms are known: 
tenascin-C, or cytotactin, which plays a regulatory role on neuron morphology and 
adhesion, representing the most abundant form [17], tenascin-X, whose gene is on 
chromosome 6 and is typically detected in muscles, tenascin-Y distributed on 
muscletendon junctions, tenascin-J or janusin, exclusive of the nervous tissue and 
tenascin-R which is synthesized by oligodendrocytes during mielinization [18]. 
Tenascin-C is mostly expressed in the mesenchymal villi, cell islands and 
columns. These structures are the proliferating units of the villous trees. Probably 
this molecule is involved in angiogenesis. 
In addition, tenascin separates fibrinoid deposits at the surface of the villous trees 
from the fetal stroma. This location suggests a role of such protein in placental 
repair mechanisms and in immunoprotection of fetal tissues [19]. 
In the present study we have investigated the placental expression of non collage 
nous ECM components such as fibronectin and tenascins in pregnancies 
complicated by FGR with or without PE, with abnormal umbilical artery Doppler 
findings. Our attention was particularly appointed on the expression of tenascin-C, 
as this protein is involved in various aspects of cell and tissue development and in 
cell-to-cell and cell-to-substrate adhesion. 
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Our study includes a control group of healthy pregnancies with appropriate fetal 
gestational age and normal umbilical artery Doppler waveforms. 
 
Patients and Methods  
Patients  
A number of 33 Caucasian pregnant women were recruited between January 2010 
and December 2013. On the total, 23 patients affected by FGR, with or without 
PE, were considered for the study group (group A). All patients of the group A 
were submitted to cesarean section. The control group (group B) consisted of 10 
pregnant women with appropriate fetal growth, homogeneous for age, BMI (20-25 
kg/m2), socioeconomic status and gestational age to the group A (Table 1). In the 
group B, abnormal presentation and previous cesarean section were the indications 
for cesarean section. Gestational age was calculated using the crown-rump length 
ultrasonographic determination in the first trimester, according to the last 
menstrual period. Ultrasound criteria were applied to assess fetal growth. Fetuses 
were considered Appropriate for Gestational Age (AGA) if Abdominal 
Circumference (AC) was found between 10th and 95th percentile. Fetuses were 
considered affected by FGR, if abdominal circumference was found below the 
10th percentile of our standard population fetal growth curves. At delivery, 
neonates were consisted Low Birth Weight (LBW) if neonatal weight was less 
than 2,500 g and Very Low Birth Weight (VLBW) if less than 1,500 g.  
PE complicated 11 cases out of 23 of the group A. At delivery, placental tissue 
was collected with the permission of the local research, Ethics Committee and with 
the informed consent of all patients. Clinical characteristics of the two groups were 
compared by the one-way ANOVA test. 
 
Doppler evaluation  
The Doppler evaluation of umbilical artery resistance was performed within four 
hours from delivery in both groups. Doppler signals were obtained using an Echo 
Color Doppler Samsung Medison A30 and an Echo Color Doppler Samsung 
WS80 combined with a 3.5 MHz convex probe. The Doppler sample volume was 
placed on a free-floating tract of the umbilical cord during fetal quiet status. A near 
zero insonation angle was obtained for every Doppler examination. To analyze the 
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Doppler flow velocity waveforms, the Pulsatility Index (PI) was automatically 
calculated (maximum velocity–minimum velocity/mean velocity) and the average 
of three consecutive measurements was used for analysis to minimize intra-
observer variability. Doppler findings were considered as mild if PI values were 
above the 2SD of the mean for gestational age based reference standards, moderate 
when the End-Diastolic Flow Was Absent (AEDF), severe when the End Diastolic 
Flow was Reversed (REDF). All measurements were performed by a single 
experienced investigator (G. N.) to minimize inter-observer variability. 
 
Immunohistochemistry  
Normal and pathological placental tissue samples were randomly harvested from 
both maternal and fetal side. Specimens were fixed and embedded in paraffin or 
cryopreserved at – 80°C. 5 μm-thick serial sections were cut, mounted on slides, 
and immunostained for Tenascin (Sigma, St. Louis, MO, USA, mouse monoclonal 
IgG) and Fibronectin (Sigma, rabbit polyclonal IgG) as previously described [20]. 
Briefly, immunohistochemistry was performed with indirect immunofluorescence 
technique: sections were incubated for 30 minutes with 10% serum derived from 
the species in which the secondary antibody was raised, and subsequently with 
primary antibody for 60 minutes at 37oC. After PBS washes, slides were incubated 
with rhodamine or fluoresce in conjugated anti-rabbit or anti-mouse IgG antibody 
for 60 minutes at 37oC. Nuclei were labeled with DAPI for 15 minutes at room 
temperature before the final washes in PBS and sections were then mounted in 
Vectashield. Signal was visualized with a Leica DMLB fluorescence microscope. 
Negative controls were included for each staining using an isotype-matched non-
specific antibody. Microscopic analysis was performed by three independent 
observers, using a four point arbitrary scale ranging from 0 (total absence of 
immunopositivity) to 3 (very strong immunopositivity), and pictures were taken 
with digital camera connected to the microscope (Leica DC200). 
 
 
RT-PCR  
RT-PCR was used to analyze target gene expression in the present study. Total 
RNA was isolated by lysing frozen tissue samples (150- 300 mg) in Trizol solution 
(Life Technologies, GIBCO BRL) according to the supplier’s protocol. RNA was 
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precipitated and quantified by spectroscopy. 1 μg of total RNA of each sample was 
reversely transcribed using the First-Strand cDNA Synthesis Kit (Amersham 
Pharmacia Biotech) according to the protocol supplied by the manufacturer. The 
random hexamer primers provided in the kit were used. The same cDNA product 
obtained from each sample was used for subsequent PCR amplification with the 
primer sets prepared for the target gene and GAPDH housekeeping gene. The 
amplification of the GAPDH gene was used as double internal control. The ratio 
between the samples and the housekeeping gene was calculated to normalize for 
initial variations in sample concentration and as a control for reaction efficiency. 
Primer sequences were designed using the software Primer 3 (developed by Steve 
Rozen, Helen J Skaletsky) available on-line at http://www-genome.wi.mit.edu. 
Semiquantitative Polymerase Chain Reaction (PCR) was performed using the 
following conditions: 95°C, 5 min initial denaturing phase; 95°C, 1 min; 55°C, 1 
min; 72°C, 1 min for 35 cycles; 72°C, 10 min, final extension. The reaction was 
carried out in a total volume of 50 ml containing 3 μl of cDNA, 10-20 pmol of 
each primer, 200 mM each of dNTP, 1.5 mM MgCl2 and 1 unit of Taq polymerase 
with the reaction buffer supplied with the kit. In each experiment, possible DNA 
contamination was determined by a control reaction in which cDNA was omitted 
from the reaction mixture and replaced by DNAse and RNAse free water. 
The amplified products (12 μl of each sample) were analyzed by electrophoresis in 
a 2% agarose gel containing ethidium bromide, followed by photography under 
ultraviolet illumination. The levels of mRNA were estimated by densitometric 
scanning and normalized against GAPDH loading controls. Densitometric analyses 
of the PCR products were performed using the ImageJ v1.29 software (developed 
by Wayne Rasband) available on-line at http://rsb.info.nih.gov/ij/. All PCR 
products were purified using QIAquick PCR purification kit (Qiagen, Santa 
Clarita, CA, USA) and their identities verified by automated DNA forward and 
reverse sequencing using adideoxy terminator reaction chemistry for sequence 
analysis on the Applied biosystem Model 373A DNA sequence.  
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Results  
Patients  
Clinical characteristics of the two groups are shown in Table 1. No difference for 
age, parity and gestational age at delivery was found between the two groups. Both 
neonatal and placental weight were lower in the study group than in the control 
group (p<0.001). Increased perinatal morbidity was observed in the study group 
(p<0.001). Group A babies were further divided in two groups according to birth 
weight: 10 LBW and 13 VLBW neonates were found. PE was detected in 5 out of 
10 pregnancies with LBW infant and in 6 out of 13 pregnancies with VLBW 
infant.  
 
Doppler evaluation  
Normal umbilical artery Doppler pattern was found in the control group (Figure 
1a). Increased umbilical artery PI values above 2DS for our normal curves were 
found in all LBW fetuses (Figure 1b); AEDF (Figure 1c) or REDF (Figure 1d) 
were detected in all VLBW fetuses.  
 
Immunohistochemistry  
Fibronectin showed a normal distribution without significant differences between 
control and FGR placentas, with or without Doppler anomalies. Immunopositivity 
for Tenascin was very weak in healthy placentas (Figure 2), when compared with 
the FGR ones, where Tenascin was strongly expressed in both maternal and fetal 
side, with a mosaic-like pattern of distribution. To better relate Doppler findings 
with immunohistochemistry, Tables 2A and 2B show the Immunohistochemical 
and Doppler findings in the study group. Table 2A, in particular, regards low birth 
weight FGR. Table 3 shows Immunohistochemical observations as well as 
Doppler findings in the control group with appropriate birth weight (AGA).  
 
RT- PCR  
RT-PCR analysis allowed the comparison between the two groups of patients in 
terms of tenascin synthesis (Figure 3). Tenascin-C and tenascin-X were low in 
placentas from the control group, while they were synthesized in all the placental 
specimens from the group A. The expression of tenascin subunits was not affected 
23 
 
by individual variability in pathological specimens, but it is reasonable that its 
amount might be related to different gestational age.  
Discussion  
Placentation requires extensive vasculogenesis and subsequent angiogenesis with 
deep ECM involvement in tissue remodeling. Impaired placental perfusion and 
angiogenesis, resulting in placental pathology, are considered the most important 
causes of FGR [4,5]. According to umbilical Doppler analyses, FGR fetuses have 
been subdivided in groups of progressive severity [21]. Correlations between acid-
base balance and Doppler findings show that only the most severe FGR fetuses 
have impaired oxygenation and acid-base balance [22].  
Many studies documented severe histological and morphological abnormalities in 
placentas of affected fetuses [7,8,23,24]. In a previous investigation, we 
approached some factors involved in the balance between the oxidative stress and 
the expression of molecules preventing and/or protecting tissues, like SOD, MMP-
2 and MMP-9, and some receptors for angiogenic factors, i.e. Vascular Endothelial 
Growth Factor Receptor (VEGFR)-2 and angiopoietin-1 receptor. We found that 
extracellular SOD, the main anti-oxidant enzyme in vascular wall, was 
significantly reduced in FGR placentas. As regards angiogenesis, we observed an 
increased expression of VEGFR-2 (early marker of neoangiogenesis) and a 
reduction of angiopoietin-1 receptor (marker of mature vessels) in FGR placentas. 
Moreover, MMP-2 and MMP-9 were constantly reduced in IUGR placentas. We 
hypothesized that oxygen levels affect ECM remodeling by MMP and 
neoangiogenesis as a consequence [25]. In another earlier study, we found 
extracellular matrix abnormalities more evident in fetuses affected by FGR with 
AEDF or REDF in umbilical artery [22]. These findings prompted us to 
hypothesize that the ECM structure plays a critical role in umbilical artery Doppler 
velocimetry regulation. An increased ECM stiffness and the consequential changes 
in the pressure gradient between fetus and placenta may exert an effect on the 
development of FGR and on the onset of abnormalities in Doppler findings in 
umbilical artery. Tenascin is poorly expressed in adult normal tissues, but it is 
involved in many wound repair mechanisms [14], being a peculiar ECM 
component mainly expressed during embryonic and tumor growth, but weakly in 
term placenta. In human placenta tenascin is expressed in a mosaic-like way in the 
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mesenchymal villi, cell islands and cell columns during the developmental 
placental stages [26].  
Castellucci et al. [14,19] have investigated the expression of this molecule in the 
placenta as related to epitelial-mesenchymal interaction, cells proliferation and 
fibrin deposition. It is particularly interesting to study its expression and its 
distribution inside an organ like placenta, which has a very high metabolic activity 
and homes a lot of different cell population. In fact, some authors have 
hypothesized an immunomodulation and fetal protection function for tenascin; 
under this point of view, our observation that this protein strongly increases during 
PE supports the theory of a maternal immune system involvement in this kind of 
pathology.  
Indeed tenascin distribution through gestation seems to suggest that this molecule 
plays a pivotal role in placental development. Also a positive modulation of cell 
migration seems to be due to this protein: it is well known, in fact, that it is 
involved in the detachment of neoplastic cells during breast cancer and in other 
kinds of neoplasm, as tenascin rich basal lamina are easily crossed by cells and 
molecules [35]. All these functions are particularly and characteristically expressed 
during early Placentation, becoming progressively less evident with placental 
physiological ageing [28]. Since tenascin C and X immunopositivity is very low in 
term placenta, it was surprising that tenascin X was often highly expressed in FGR 
specimens we studied, with a “mosaic” distribution within placental tissue.  
Tenascin expression was more weak in the FGR fetuses with severe umbilical 
Doppler findings (ARED); on the contrary, it was very strong in the early gestation 
as well as in the FGR fetuses with moderate alteration in Doppler findings (PI> 
2SD).  
The presence of tenascin in the media of larger blood vessels of tumors and in 
capillary walls might be related with an angiogenic activity of this molecule, as 
improved tenascin-mediated angiogenesis and wound repair mechanism might be 
considered a compensatory mechanism in case of growth restriction with LBW.  
The weak tenascin immunoreactivity in FGR fetuses with VLBW could be 
considered as a failed compensative mechanism of placental wound repair and 
angiogenesis.  
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Between the 28th and 32nd week of gestation, the reappearance of end diastolic 
flow in umbilical artery could lead to an improvement of abnormal umbilical 
artery velocimetry with less severe FGR, or to a persistent ARED flow that lead to 
the most severe FGR associated with abnormal umbilical artery Doppler 
velocimetry [29-31]. It is highly suggestive that these fluctuating values depend on 
wound repair mechanisms which operate during placental development.  
 
Conclusion  
Based on our results, strong tenascin immunoreactivity could be considered as a 
marker of improved wound repair and angiogenesis in these FGR fetuses with 
better perinatal outcome. Finally, impaired umbilical artery Doppler velocimetry 
with persistence of end diastolic flow would be possible when the wound repair 
mechanism in placental tissue does not fail. An ongoing study has been settled to 
verify if tenascin or related metabolites can be sampled in cervico-vaginal fluid. 
On these bases, tenascin could be a tailor biomarker of placental angiogenesis in 
FGR fetuses who have the possibility to respond to chronic hypoxia due to 
placental insufficiency. 
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Intrauterine growth restriction and fetal cerebral 
redistribution.  Risk stratification and neurological 
outcome. 
 
The fetal brain is particularly vulnerable to the effects of intrauterine 
growth restriction (IUGR) (5). Long-term neurological disorders such 
as cerebral palsy and epilepsy, as well as learning and attention 
difficulties, neurobehavioural disabilities, and other cognitive and 
sensory issues have been attributed to restricted growth of the fetus 
(29). The long-term care of a child with compromised brain 
development is associated with emotional stress for families and a 
direct cost on society. Currently there are limited treatments to prevent 
neurological impairment in the IUGR neonate (5). 
Fetal growth restriction is a complex process, and a delayed diagnosis 
is associated with increased perinatal morbidity with neurological 
impariment and mortality; IUGR occurs in approximately 5 e 10% of 
pregnancies. The term refers to poor growth of a fetus while in the 
mother's womb during pregnancy; is a term used to describe a baby 
who is smaller than the usual amount for the gestational age due to 
pathological compromise. Placental insufficiency or utero-placental 
dysfunction results in insufficient blood flow to the placenta during 
pregnancy and inadequate supply of nutrients and oxygen to support 
normal growth of the fetus. Thus, the fetus develops in a chronic 
hypoxic environment. Placental insufficiency can result in changes in 
fetal metabolism, hormones, hematology, immunology and 
cardiovascular function. 
The fetus hemodynamically adapts to this pathology (detected by an 
increase in the umbilical artery pulsatility index—UAPI) through the 
vasodilation of cerebral circulation (detected by a decrease in the 
middle cerebral artery pulsatility index—MCAPI). The resulting 
hyperperfusion is considered pathological (29
b). This ‘brain-sparing 
effect’ is associated with an abnormal cerebral/umbilical ratio that 
quantifies the redistribution of cardiac output by dividing the Doppler 
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indices of the middle cerebral artery (MCA) with that of the umbilical 
artery (UA). During pregnancy M1 tract pulsatility’s indice (initial 
landmark), are lower than those from M2 tract (distal part at the 
extreme wings of large sfenoid), with statistically significant 
differences. But, when a depletion of the mechanisms of compensation 
occurs, damage to brain tissue can be seen. The loss of these 
mechanisms, following the persistence of hypoxia, causes the 
activation of the cascade of vascular, metabolic and biochemical 
events, with the releasing of free radicals, typical in case of ischemia 
with apoptosis and irreversible neuronal necrosis. 
Aim of this study was to asses changes in cerebral blood flow in the 
proxymal (M1) and in the distal tract (M2) of middle cerebral artery in 
severely growth restricted fetuses in relation to neonatal outcome and 
neurological morbidity at 2 years of age. 
 
Patients and Methods  
This is a prospective observational study. The participants were 
identified from a cohort of single infants born alive between May 2013 
and December 2014 in a single academic center (a level III perinatal 
center in Naples) and then recruited for the follow-up study at 1-2 
years.  
Patients were considered to be at risk for fetal growth restriction if they 
had a fetal abdominal circumference (AC) <5th centile or calculated 
estimated fetal weight (EFW) <10th centile (13, 30). 
Inclusion criteria included gestational age between 24 0/7 and 36 6/7 
weeks and an EFW than 500 g or greater; patients were recruited if they 
had ultrasound examination of the dating of pregnancy and if they had 
more than one sonographic examination performed at a greater than 2-
week interval. Patients were excluded from analysis for the following: 
fetal death, major fetal defect, presence of twins, lack of a complete 
Doppler evaluation and lack of a delivery record. Patients with fetal 
growth restriction were managed according to our institutional 
protocol, with indications for delivery at gestational age ≥ 34 weeks, a 
suspected nonreassuring fetal status based on antenatal testing, 
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progression to reversal of end-diastolic flow, and other obstetric 
indications such as the development of preeclampsia. 
Antenatal surveillance should provide longitudinal assessment that is 
designed according to the severity of the fetal condition, and directs 
appropriate intervention to improve outcomes. 
All sonographic examinations were performed in a single ultrasound 
unit. Biometry was performed by measuring the biparietal diameter, 
head circumference, abdominal circumference, and femur length using 
the equations of Hadlock et al (31) for calculation of the estimated fetal 
weight. The umbilical artery (UA) and middle cerebral artery Doppler 
waveforms were recorded using color Doppler and the pulsatility index 
(PI) was calculated according to a standard protocol; umbilical artery 
Doppler findings were obtained and the umbilical artery was 
considered abnormal if the pulsatility index was above the 95th 
percentile, if there was absent end-diastolic flow, or if there was 
reversal of end-diastolic flow (32); we evalueted the occurence of brain 
sparing effect in middle cerebral artery (circle’s centralization). 
After birth and before the clamp, has been evalueted a determination of 
pH and acid-base balance; the infants were then evaluated at 1 and 2 
years of life for evaluation of neurological outcomes.  
The children included in the study were followed up in the first 24 
months of life through dedicated pediatric outpatient clinic. For 
neurological evaluation was used Amiel-Tison neurological 
examination – ATNE; we considered mild psychomotor retardation for 
QS = 71-85. The Griffiths Mental Development Scales is used to 
measure the rate of development of young children; the six areas of 
development measured by the scales include: Locomotor, Personal-
Social, Hearing and Language, Eye and Hand Co-ordination, 
Performance and Practical Reasoning.  
10 children were lost to follow up at 24 months.  
The birthweight values were converted into centiles and Doppler 
parameters converted into multiples of median (MoM), adjusting for 
gestational age using reference ranges. 
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Adverse perinatal outcomes evaluated included cesarean delivery for 
fetal bradycardia, umbilical artery pH less than 7.0, 5-minute Apgar 
scores less than 7.0, respiratory distress syndrome and major 
complications: perinatal death or irreversible damage to organs. 
The demographic characteristics and gestational age at the initial dating 
sonography were similar between our study groups.  
Data were analized by ANOVA test, using the SPSS statistical 
software.  
 
Results 
The patients were classified according to middle cerebral artery 
Doppler into two groups: A group (28 fetuses) presented “abnormal 
ACM” (loss of BSE in M2), and abnormal UAPI (>95th percentile, 
absent or reversed umbilical artery end diastolic velocity); B group (36 
fetuses) with brain sparing effect in both M1 and M2 and abnormal 
UAPI.  
The average weight was 1075.62±264.06 SD (gr); the mean gestational 
age at birth was 32.61±2.37 SD (weeks). 
The A group show a greater number of days admission to the NICU 
(26.1±15.92 days), gestational age was lower and cesarean delivery 
own to suspected fetal distress were more frequent (17.8% vs 8.3%). 
There were no differences in acidosis at birth (umbilical artery pH). 
None of the infants had a 5-min Apgar score < 7. We found a 
significantly reduced growth rate in fetuses with an abnormal ACM 
(56% birth weight <3th percentile), as opposed  to those with normal 
umbilical artery Doppler findings. 
The fetuses of B group had demonstrated a better neonatal outcome 
than A group. 
Two cases of cerebral palsy have been described in group A 
(momoplegia and diplegia associated with strabismus). 
It was found an inverse relationship between umbilical artery pulsatility 
index and percentile at birthweight; also the estimated fetal weight 
below the 3th percentile for gestational age has been shown to be 
associated with the loss of brain sparing effect in M2 tract.  
37 
 
 
Birth weight less than 1000 g showed a worse neurological outcome at 
one and two years of life (p 0.0); weight <3th centile is correlated with 
a delayed psychomotor development at 12 months (p 0.03) (we do not 
observe a correlation with the neurological examination at 24 months 
probably for a loss to follow up). Psychomotor development shows a 
positive trend in correlation with birth weight percentiles, at 12 months 
(p 0.06). 
By analizing all infants, QS 12 mean was 100.05±7.106; QS 24 mean 
was 98.75±10.953. 
 
Discussion 
These results suggest that fetal cerebral redistribution is a risk factor for 
IUGR infants and that loss of compensation’s mechanism identifies 
those experiencing greatest weakness. 
On the other hand, the persistence of an adaptive response like BSE 
allows a behavior of waiting to implement the preventive therapy for 
prematurity / immaturity, for example; but it is also, possible that 
delayed childbirth results in a worsening of prognosis. 
Longitudinal studies suggest that fetal Doppler parameters change 
progressively during fetal deterioration: ductus venosus becomes 
abnormal at later stages of fetal compromise. Their combined use in 
clinical algorithms, might provide opportunities for the assessment of 
fetal wellbeing. 
Concerning brain Doppler, the multicenter study of Baschat et al. 
reported an relative risk of 3.3 for neonatal morbidity in fetuses with 
abnormal MCA Doppler. Of note, IUGR fetuses with normal MCA 
Doppler were similarly at risk of detected cranial abnormalities when 
compared to normal preterm newborns, reflecting its high negative 
predictive value. 
The middle cerebral arteries supply the majority of the lateral surface of 
the hemisphere, except the superior portion of the parietal lobe and the 
inferior portion of the temporal lobe and occipital lobe. In addition, 
they supply part of the internal capsule and basal ganglia. In its territory 
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lie the motor and sensory areas (distal part) excluding leg and perineum 
and auditory and speech areas. It is not a coincidence that in advanced 
stages of fetal compromise we witness the worst changes in biophysical 
profile with reduced fetal movements too (33). 
Since in our managing protocol, MCA Doppler was used as additional 
criterion for elective delivery, the results of A group might substantiate 
the current use of the MCA Doppler as a sonographic marker for 
quantification of placental insufficiency and centralization of fetal 
blood flow, including as indicator of poor outcome and reduced fetal 
growth rates.  Lower growth rates have been correlated with increased 
perinatal morbidity (33) although an absolute cutoff at which this risk 
increased has yet to be determined. 
Delivery at lower gestational ages results in risk of significant 
complications of prematurity. This information is clinically useful in 
that it would distinguish those patients most likely to benefit from 
aggressive measures, such as maternal hospitalization, maternal transfer 
to a tertiary care center, aggressive fetal monitoring, administration of 
corticosteroids to promote fetal maturation and magnesium for 
neuroprotection, when indicated. 
Our findings suggest that IUGR infants with an abnormal MCA are at 
increased risk for poorer outcomes and could develop deficits in 
cognitive functioning in childhood.  
We conclude that the MCA Doppler assessment, in addition to the UA 
Doppler, may be a clinical tool to differentiate patients with FGR that 
may progress more rapidly towards the delivery to earlier gestational 
age and therefore more likely will benefit from an increased level of 
surveillance.  
From a clinical perspective, the prediction of neurological morbidity is 
a major challenge in modern obstetrics and lays the basis for timely 
delivery and future preventive interventions. 
 
Pending submission 
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 Birth Weight Gestational 
Age 
N 
Valid 73 73 
Missing 0 0 
Mean 1075,62 32,612329 
Median 1090,00 33,000000 
Std. Deviation 264,060 2,3791306 
 
 
 
 
 
 
Neurological 
Examination 12 
months 
Frequency Percentile 
Valid 
1 66 90,4 
2 4 5,5 
3 1 1,4 
5 1 1,4 
Total 72 98,6 
Missing System 1 1,4 
Total 73 100,0 
 
 
 
Birth Weight 
Percentiles 
Frequency Percent 
Valid 
1 41 56,2 
2 13 17,8 
3 19 26,0 
Total 73 100,0 
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Neurological 
Examination 24 
months 
Frequency Percent 
Valid 
1 59 80,8 
2 3 4,1 
5 1 1,4 
Total 63 86,3 
Missing System 10 13,7 
Total 73 100,0 
QS 12 months Frequency Percentile 
Valid 
1 64 87,7 
2 2 2,7 
3 1 1,4 
6 5 6,8 
Total 72 98,6 
Missing System 1 1,4 
Total 73 100,0 
QS 24 months Frequency Percentile 
Valid 
1 54 74,0 
2 3 4,1 
3 2 2,7 
4 1 1,4 
5 2 2,7 
6 2 2,7 
Total 64 87,7 
Missing System 9 12,3 
Total 73 100,0 
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NE neurological esamination 
QS psychomotor development 
 
 
 
OUTCOME  A Group 
(28)  
B Group 
(36)  
 
P value  
pH  7,25±0,12  7,28±0,09  0.838  
    
acid-base 
balance 
-5,40±3,89  -4,76±3,30  0.64  
    
5-min Apgar 
score 
0  0  1.000  
 
Cesarean 
delivery  
1  10  1.000  
    
    
Admission NICU 
days  
26.1±15.92 8.81±11.54 0.08  
      
 
 
 
 
 
 
 
 
 
 
 NE 12 months 
Birth weight 
NE 24 months 
Birth weight 
 
QS 12 months 
Birth Weight Percentiles 
P 
value 
0.0 0.0 0.03 
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II Research line : Therapy and prediction of preterm 
birth in singleton pregnancies at low risk and high-risk 
twin pregnancies  
 
Definitions of ‘preterm’, ‘term’ and ‘post-term’ birth have been 
specified by the American Academy of Pediatrics, American College of 
Obstetricians and Gynecologists, and the World Health Organization 
(34, 35). Accordingly, preterm birth occurs ≤ the last day of the 37th 
week (day 259) and  is defined by the presence of regular uterine 
contractions and progressive dilation of the cervix. 
Preterm birth can be the result of three obstetrical circumstances: 1) 
preterm labor with intact membranes (50%); 2) preterm prelabor 
rupture of membranes (PROM) (30%); and 3) “indicated” preterm 
birth, which occurs when maternal or fetal indications require delivery 
before 37 weeks of gestation (20%). The most common indications are 
preeclampsia and small for gestational age (SGA). 
The increased vulnerability of moderate preterm infants (moderate PT) 
(32
0/7
-33
6/7
 weeks of gestation) and late preterm infants (late PT) 
(34
0/7–366/7) in the neonatal period is now widely accepted (36, 37) and 
undoubtedly these infants have both excess morbidity and mortality. 
A recent executive summary of proceedings from a joint workshop 
sponsored by the Society for Maternal–Fetal Medicine, the National 
Institute of Child Health and Human Development (NICHD), the 
Section on Perinatal Pediatrics of the American Academy of Pediatrics 
(AAP), and the American College of Obstetricians and Gynecologists 
(ACOG), in which a diverse group of experts were invited to 
participate, defined periviable birth as delivery occurring from 20 0/7 
weeks to 25 6/7 weeks of gestation; the survival varies per week from 
6%, 26%, 55% to 72% (Raju 2014). 
15 million babies are born too soon every year; more than 1 in 10 
babies are born preterm, affecting families all around the world. Over 1 
million children die each year due to complications of preterm birth. 
Many survivors face a lifetime of disability, including learning 
disabilities and visual and hearing problems. There is a dramatic 
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survival gap for premature babies depending on where they are born. 
For example, over 90% of extremely preterm babies (<28 weeks) born 
in low-income countries die within the first few days of life; yet less 
than 10% of babies of this gestation die in high-income settings, a 
10:90 survival gap (38). Furthermore, mortality for extremely preterm 
infants (22 – 26 weeks) is  reduced in centres  offering the highest level 
of intensive care (tertiary centres), compared with less specialist centres 
(OR 0.73 (95% CI 0.59 to 0.9)), supporting the recommendation that 
care is centralised. Transport of these infants during the first 48 hours 
is, however, associated with increased rates of severe IVH (39) and 
babies born in tertiary centres have significantly better morbidity free 
survival than infants transferred there after birth (OR 1.92 (95% CI 
1.02 to 3.6)) (40). While the difference in morbidity is likely 
multifactorial, the findings emphasise the importance of coordinated 
neonatal and obstetric network strategies for safe antenatal 
centralisation and improving neurodevelopmental outcome for preterm 
infants is an important challenge for neonatal medicine. The disruption 
of normal brain growth and neurological development is a significant 
consequence of preterm birth and can result in physical and cognitive 
impairments. While advances in neonatal medicine have led to 
progressively better survival rates for preterm infants, there has only 
been a modest improvement in the proportion of surviving infants 
without neurological impairment, and no change in the proportion with 
severe disability (39). The overall number of children with 
neurodisability due to prematurity is increasing. 
In the preterm infant, defining hypoxic–ischemic injury (HII), its 
clinical course, monitoring, and outcomes remains complex. Few 
studies examine preterm HIE, and these are heterogeneous, with 
variable inclusion criteria and outcomes reported. 
Although many preterm births remain unexplained, in high-income 
countries, their rise was associated with increasing maternal age at 
delivery, the greater use of assisted reproductive technologies resulting 
in higher frequency of twin pregnancies and in some countries, 
cesarean sections performed before the 39th week of gestation. By 
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contrast, the causes most frequently associated with preterm delivery in 
low-income countries are infections, malaria, HIV and the increased 
frequency of teenage pregnancy along with social deprivation and the 
lack or insufficiency of care at preconception period, pregnancy and 
childbirth. 
Given the high incidence of preterm birth and its sequelae, it is 
necessary to investigate the multiple pathogenic mechanisms 
underlying this syndrome, so as to implement an etiological therapy to 
prevent neurological injury. Considering, therefore, the multifactorial 
etiology, is not justifiable or recommended a single treatment for all 
pregnant women. It is necessary, however, to recognize, change and 
delete the risk factors and identify and treat early high-risk patients.  
The common pathway of parturition has been defined as the 
anatomical, physiological, biochemical, endocrinological, 
immunological and clinical events that occur in the mother and/or fetus 
at the time of parturition regardless of whether this occurs at term or 
preterm (41). The most well-known components of the common 
pathway of parturition are the uterine components because they are 
clinically apparent to obstetricians and patients. Such components 
include: 1) increased myometrial contractility; 2) cervical 
ripening/dilatation and effacement; and 3) membrane/decidual 
activation. The onset of spontaneous labour at term is the result of 
physiological signals and in most cases there is synchronous activation 
of the common pathway; whereas preterm parturition is the 
consequence of pathological signals that activate the common pathway 
of parturition and the activation may be asynchronous.  
It is usually difficult to identify all causes of preterm labor. However, 
we can refer two groups: 
1. 1. related to inflammatory-infectious disease  
Account for about 25-40% of the cases as documented by 
microbiological and histological studies on amniotic fluid, placenta and 
membranes.  
The mechanisms by which intrauterine infections lead to preterm 
labour are related to activation of the innate immune system (42). 
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Liggins was the first to liken cervical ripening to an inflammatory 
response. Microorganisms can gain access to the amniotic cavity by: 
(1) ascending from the vagina and the cervix (the most common 
pathway ); (2) haematogenous dissemination through the placenta; (3) 
accidental introduction at the time of invasive procedures; and (4) by 
retrograde spread through the fallopian tubes. Microbial endotoxins and 
proinflammatory cytokines stimulate the production of prostaglandins, 
other inflammatory mediators, and matrix-degrading enzymes. 
Prostaglandins stimulate uterine contractility, whereas degradation of 
extracellular matrix in the fetal membranes leads to PPROM. 
2. On a non-inflammatory basis: uterine ischaemia, uterine 
overdistension, abnormal allogenic recognition, allergic-like reaction, 
cervical disease, endocrine disorders.  
Most of these mechanisms of disease operate in non-pregnant women. 
It is also possible that preterm parturition may be caused by 
mechanisms of disease that are unique to the maternal–fetal 
relationship (43), because of its unique anatomy, physiology, 
immunology and metabolic demands. Consequently, we remain open to 
the discovery of undescribed mechanisms of disease during pregnancy.  
For an optimal prevention of PTB, risk stratification should be based on 
a combination of risk factors, obstetric history, and screening tools. 
Defining risk factors for prediction of preterm birth is a reasonable goal 
for several reasons. There are many maternal or fetal characteristics 
that have been associated with preterm birth, including maternal 
characteristics, pregnancy history, present pregnancy characteristics, 
psychological characteristics, adverse behaviours, infection, uterine 
contractions and cervical length, and biological and genetic markers. 
The recurrence risk in women with a previous preterm delivery ranges 
from 15% to more than 50% and this risk is inversely related to the 
gestional age of the previous preterm birth (44). 
These risk factors, however, are neither sensitive nor specific, so most 
of the women who give birth preterm are not identified on a risk basis 
and most women considered at high risk do not give birth preterm. In 
addition, its accuracy is particularly low among primiparous mother. 
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Delaying childbirth can reduce long-term morbidity, promoting the 
development of organs and systems. Corticosteroid administration 
before anticipated preterm birth is one of the most 
important  antenatal therapies available to improve newborn outcomes.  
The need for early treatment leads often to unnecessary hospitalization 
of patients with considerable engagement of human and financial 
resources and the use of drugs with potential side effects for the mother 
and the fetus. For this reason new predictive markers have been 
explored. 
Evaluation of the gravid cervix uteri is an important part of prenatal 
care, especially in the patient at risk for preterm birth. Seeking a 
method of cervical length measurement that could be used easily 
regardless of patient habitus, location of the cervix, and gestational 
age, it’s used ultrasound cervical length measurements that can help 
identify women at risk; another sonographic finding in pregnancies at 
risk of preterm delivery is ‘funneling’ or dilatation of the internal os.  
Early identification of women at risk allows early detection of 
threatened preterm delivery and this is one of the main goals in 
obstetric care. 
The therapeutic approach to the prevention and care of preterm delivery 
is based on the use of different tocolytic agents with the aim to stop 
labour for at least 48 hours, to accelerate the pulmonary maturity of the 
fetus and reduce the incidence of respiratory distress syndrome and 
intraventricular hemorrhage. The second leading objective is to reduce 
perinatal mortality and morbidity related to severe prematurity (45); 
tocolytic agents are recommended by 24 + 0 to 33 + 6 weeks. Several 
drugs at same time is not recommended for the significant increase of 
maternal and fetal adverse events; tocolysis without the concomitant 
use of corticosteroids and maintenance therapy for a period longer than 
48 hours are not supported by evidence of effectiveness. The tocolytic 
agents used are: magnesium sulphate, prostaglandin-synthetase 
inhibitors, calcium-antagonists, progesterone, b-mimetics and oxytocin-
antagonists. In early gestational age of 22 to 28 weeks gestation to 
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delay childbirth than a day causes an increase in neonatal survival of 
3%. 
The PTB rates have increased over the last 30 years; a delay in delivery 
means not only decrease the psychological and social implications 
related to the problem, but also reduce the economic costs of intensive 
and protracted neonatal care. The "cost" of a preterm birth should be 
evaluated both in a psycho-social context is purely economic zone. 
It should be remembered, in fact, the strong impact that premature birth 
can have both on the child, with the beginning of learning difficulties or 
disabilities, either on the parents when these complications cause much 
discomfort and emotional distress often long term. 
Romero R has argued that obstetrical disorders are really syndromes, as 
well as preterm delivery, and refers to them as “The Great Obstetrical 
Syndromes” (46). The features of “The Great Obstetrical Syndromes” 
are the following: 1) multiple aetiology; 2) long preclinical stage; 3) 
frequent fetal involvement; 4) clinical manifestations which are often 
adaptive in nature; and 5) predisposition to a particular syndrome is 
influenced by gene–environment interaction and/or complex gene–gene 
interactions involving maternal and/or fetal genotypes. 
Advancing the research agenda is a critical need to reduce the burden of 
preterm birth, requiring innovations for both prevention and care; 
providing quality care means doing the right thing at the right time. 
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Objective 
 
In this study, we evaluated the effectiveness of two innovative 
treatments: the repetition of the cycle with antagonists of oxytocin in 
twin pregnancies with persistent risk of preterm delivery and the use of 
'docosahexaenoic acid’ (DHA) endovaginal in symptomatic women at 
low risk with contractile activity uterine acute. Also we assessed the 
PartoSure Test that is a rapid, non-invasive strip test for the detection of 
placental alpha microglobulin-1 (PAMG-1) in patients presenting with 
signs and symptoms of preterm  labour; this test is most useful in cases 
where cervical  length measurement (CL)  is between 15 and 30 mm 
and the predictive value of CL is lowest for prediction of spontaneous 
preterm delivery within 7 days in patients with threatened preterm 
labour. 
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Abstract 
Twin gestation contributes significantly to perinatal morbidity and 
mortality related to high occurrence of preterm birth. We evaluated 202 
women consecutively selected with twin pregnancies and threatened 
preterm labor. 98 women were threatened with a single cycle of 
Atosiban; 34% of them delivered before 34 weeks. The study group 
consisted of 104 patients submitted to a second cycle of Atosiban 
because of regular uterine contractions and or cervical length 
modifications occurred from 48 hours to 7 days and gestational age was 
prior to 32 week of gestation (group A). After the second cycle of 
Atosiban, 49 out of 104 patients received a treatment 
with a vaginal tablet of lactoferrin (group B). After the second cycle of 
Atosiban, 84% of patients of group A and 90% of patients of group B 
delivered after 34 weeks. 
The overall rate of delivery before 34 weeks in the studies groups was 
of 16%. In our experience, repeated cycles of Atosiban have shown 
effectiveness in delaying delivery in twin pregnancies. It seems logical 
to use an oxytocin receptor antagonist as first line drugs in twin 
pregnancies because of the increased risk of pulmonary edema. 
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Introduction 
Twin gestation contributes significantly to perinatal morbidity and 
mortality related to high occurrence of preterm birth. Over the last 
decade, the number of assisted-reproduction twins have been 
increasing, doubling the twining rates in Western countries [1]. In 
addition, twin gestations imposed financial and psychological burdens 
on the family and society [2]. In Campania, a Southern region of Italy, 
the birth rate from assisted reproduction increased from 6% in 2007 to 
16,5% in 2012. Overall, the increased risk of maternal and fetal 
morbidity associated with twin compared with singleton pregnancies is 
nowadays the strongest argument for single embriotransfer in the 
debate of assisted reproduction. At least 60% of all twins are born 
before the 37th week of gestation. In the last seven years twin gestation 
in our department increased from 3.5% to 7.7% in 2013. In several 
double blind trials Atosiban has demonstrated a tocolytic effectiveness 
similar to beta agonists, with the advantages of no side effects due to its 
specific effect on uterine tissue [3,4]. 
Moreover, women with multiple pregnancy have a higher risk of 
pulmonary edema then women with singleton pregnancy. Pulmonary 
edema occurs in approximately 1/400 women treated with beta-agonists 
[5]. In twin pregnancies, the levels of urinary aldosterone are increased. 
This secondary hyperaldosteronism may be further increased by 
betaagonists, which rise both aldosterone and renin levels. This 
condition induces fluids retention and plasma volume expansion, 
leading to a greater risk of pulmonary edema [5]. 
Prevention of preterm labor is the goal of long-term tocolysis. Women 
with recurrent episodes of recurrent preterm labor are at risk for 
preterm premature rupture of membrane (pPROM), further 
cervical changes and preterm delivery [6]. Atosiban has been used in 
Reproductive Medicine Unit of the University of Naples Federico II 
from 2003 to date, as the first line tocolytic drug in women with 
threatened preterm delivery in twin pregnancy. We have previously 
reported our experience in a small series of twin pregnancies submitted 
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to a second treatment with Atosiban because the presence of symptoms 
and signs of preterm labor within seven days from the first treatment. 
This therapeutic approach showed to be relevant for those patients. On 
the basis of this preliminary experience, we conducted a retrospective 
cohort study, with the aim to evaluate the effectiveness of repeated 
Atosiban administration in twin pregnancies over the last ten years in 
our single centre. 
 
Material and methods 
This was a retrospective study of twin pregnancies with 276 
consecutive women from April 2003 to December 2013 conducted at 
the Reproductive Medicine Unit of the University of Naples Federico 
II. All women with twin pregnancies with threatened preterm labor 
with or without contractions and reduced cervical length were eligible 
for the study. Exclusion criteria were maternal age <18 years, fetal 
death, major fetal defect, severe twin-to-twin transfusion syndrome or 
selective fetal growth restriction, and cervical length >20mm. On the 
basis of this criteria 74 patients were excluded. 
Diagnosis at admission were: 113 preterm labors, 50 preterm premature 
ruptures of membranes, 21 incontinent cervices cerclage, 18 vaginal 
bleedings (Figure 1). On the total, 172 twin pregnancies derived from 
reproductive assisted techniques. Preterm labor was defined as ≥4 
uterine contractions / 30 min and or cervical length <20 mm with or 
without uterine contractions. pPROM was proven by a sterile speculum 
examination (RCOG guidelines N° 44/2006). Atosiban was 
administered according to the recommended protocol with an initial 
bolus of 6.75 mg in 1 minute followed by a high rate infusion of 18 
mg/hour over 3 hours and a lower concentration of 6 mg/hour over a 
period of 45 hours. During the first cycle of Atosiban, all women 
received corticosteroids prophylaxis (antenatal administration of 12 mg 
of betamethasone, followed by a second dose 24 hours later) to enhance 
lung maturation. The second cycle of Atosiban was administered when 
regular uterine contractions and or cervical length modifications 
occurred from 48 hours to 7 days after the first cycle and when 
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gestational age was prior to 32 weeks of gestation (group A) (Figure 2). 
Bacterial vaginosis was detected in 22% of women and was treated 
with antibiotic therapy; erythromycin (250 mg orally 6 hourly) was 
given for 10 days following the diagnosis of pPROM in all patients. 
After the second cycle of atosiban, 49 out 104 patients received a 
treatment with a vaginal tablet 
of lactoferrin (Lf) (300 mg) for 21 days (group B) (Figure 3). 98 
pregnant women received a single dose of Atosiban just to perform the 
corticosteroids prophilaxis in 48 hours. This group of patients (the 
control group) refers to patients evaluated before our preliminary 
reported experience. 
Statistical analysis was performed using GRAPH Pad Prism 4.0 
software (Graph-pad Software Inc, La Jolla, CA). The distribution of 
variables was compared with Student’s Test for paired data. 
Differences associated with p values lower than 0.05 were considered 
statistically significant. The results are reported as mean +/- standard 
deviation.  
 
Results 
After 48 hours from the end of the first cycle of Atosiban, 98 women 
didn’t show uterine contractions and/or cervical length modifications; 
34% of them delivered before 34 weeks. While 104 women had regular 
uterine contractions and/or cervical length modifications (group A). 
22% of those patients had recurrent symptoms of preterm labor from 48 
hours, whereas the remaining 78% 
showed symptoms within 7 days (Figure 3). After the second cycle, 
84% of patients of group A and 90% of patients of group B delivered 
after 34 weeks (Figure 4). No difference was detected between 
spontaneous twin pregnancies and assisted reproduction ones. The 
overall mean number of days gained after the start of tocolysis was 38 
in the group of preterm labor, whereas in the subgroup of women with 
pPROM the interval until delivery was 19 days; in the group B the days 
gained were 52. After initial bolus administration, only 5% of women 
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presented drug related side effects such as flushing for 1-5 minutes. 
During infusion, 3% of women experienced side effects 
possibly related to Atosiban such as nausea and vertigo. The overall 
rate of delivery before 34 weeks in the studies groups was of 16%.  
 
Discussion 
In this retrospective study repeated Atosiban administration resulted 
effective in prolonging twin pregnancies. In multiple pregnancies, over 
distension of the uterus with stretching of fetal membranes and or 
cervical ripening is a more likely mechanism for its release than 
infection or inflammation. The uterine over distension in twin 
pregnancies may cause a relative decidua ischemia with release of 
lysosomal enzymes. These enzymes include several phospholipases 
which initiate the prostaglandins cascade by releasing arachidonic acid, 
the critical substrate for their synthesis. The increased release of 
prostaglandins affects collagen integrity altering the consistence and 
distensibility of the cervix [7]. There is an inverse relationship between 
cervical length and the 
likelihood ratio for preterm birth. Atosiban acts by blocking 
oxytocinreceptors. Oxytocin seems to initiate myometrial contractility 
by both a direct and an indirect mechanism. It directly interacts with 
membrane receptors leading to an increase in intracellular calcium. The 
indirect effect of oxytocin is the stimulation of prostaglandins release 
from decidua and fetal membranes; the prostaglandins are strictly 
involved in cervical ripening [8]. 
Recently a Cochrane Database Systematic Review on oxytocin receptor 
antagonists for inhibiting preterm labor underlines the importance of 
well studies about different tocolytic strategies at different gestational 
ages in order to optimize safety and efficacy [9]. 
Furthermore, Atosiban determined fewer maternal side effects in 
comparison with other tocolytics [9]. As we previously demonstrated in 
a selected group of pregnant from ART, the use of oxytocin receptor 
antagonist in the mid second trimester would appear to be an useful 
tool to delay preterm labour when prostaglandins release activates 
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oxytocin receptors [3]. Multiple pregnancies are also associated with a 
major maternal plasma volume expansion and secondary 
hyperaldosteronism [5]. This conditions increase the risk of pulmonary 
edema, particularly when tocolytic therapy with beta agonists combined 
with fluid therapy is administered. Beta mimetics increase both 
aldosterone and renin levels in twin pregnancies and may potentiate the 
risk of pulmonary edema [5,10]. 
Moreover, same studies revealed that Atosiban is cost-saving versus 
beta mimetics, due to its superior safety profile [4,11]. In our 
experience, repeated cycles of Atosiban have shown effectiveness in 
delaying the interval to delivery, in twin pregnancies. The rate of 
preterm birth < 34week of gestation with single cycle of Atosiban was 
34% (n=33) compared with the overall rate of the studies groups of 
16%. It seems logical to use an oxytocin receptor antagonist as first line 
drugs in twin pregnancies because of the increased risk of pulmonary 
edema. In addition, the use of vaginal lactoferrin (Lf), an approximately 
80-KDa iron-binding glycoprotein of the transferrin family with 
bacteriostatic and bactericidal properties, was usefull in the 
maintenance therapy, in our experience. Several studies [8,12,13] 
suggest that Lf plays an important role against cervicovaginal 
inflammation and or infection by decreasing levels of interleukin (IL)-6 
and increasing cervical length. Both drugs, Atosiban and Lf, seem able 
in preventing preterm delivery caused by cervical ripening, blocking 
prostaglandins release. Twin pregnancies are at an increased risk of 
stillbirth, antenatal morbidity and infant death. This is largely due to 
preterm delivery and complications of prematurity and low birth weight 
are the primary risk factors for infant mortality. The NICU admission 
rate was lowest following delivery at 38 weeks’ gestation, and the 
NICU admission rate 
decreased significantly with each additional week of pregnancy from 
32 through 38 weeks’ gestational age. We found an increased risk of 
mortality associated with delivery at 34 weeks’ [14-16]. We hope that 
these data provide information to assist providers for the management 
of threatened preterm labor in twin pregnancies. Based on this 
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consideration and the safety profile of Atosiban, two cycles are better 
than one in symptomatic patients before 32 weeks of gestation, in our 
experience, even if corticosteroid prophylaxis is already performed 
This management is used to reduce perinatal morbidity/mortality due to 
extremely prematurity in those twin pregnancies with no additional 
complications that may indicate earlier delivery. In addition 
maintenance therapy using vaginal Lf improve gestational age delivery 
as showed in the study group B.  
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Summary 
Preterm labor is a public health problem and to this day, it’s the great 
challenge of modern obstetrics. We conducted a randomized double-
blind controlled study. At the admission, all patients were submitted to 
cardiotocography. Patients with regular contractions but without 
decreasing of cervical length or funneling at transvaginal sonography 
were admitted. 90 patients at 24-34 weeks of gestation were finally 
recruited. Patients were randomly divided in two groups: A group (45 
patients) received a single transvaginal dose of docosahexaenoic acid (1 
gr of DHA); B group (45 patients) received placebo. At 120 minutes, 
cardiotocographic examination was performed in all patients. A group 
showed a significant decrease in number and intensity of contractions 
(p<0.05) as compared to B group. The results of our study show that 
vaginally administered DHA during pregnancy is effective on uterine 
contractions providing a significant decrease of spontaneous 
contractions and probably reducing the risk of preterm delivery. 
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Introduction 
Preterm labor is defined as regular uterine contractions resulting in 
changes in the cervix that start between 24 weeks  of pregnancy and 37 
weeks of pregnancy. The preterm birth is the leading cause of perinatal 
mortality and morbidity, accounting for 28% of neonatal mortality 
worldwide. Although the cause is often unknown, a variety of factors 
may play a role in preterm birth; inflammation is the most common and 
most important. Vaginal infections seem to play an important role. 
Infections result in the activation of the inflammatory cascade, which 
precedes and causes the shortening of the cervix. On this basis, we 
focused our studies on inflammatory mediators, including cytokines 
and chemokines, in women’s cervix [2]. The fatty acids are precursors 
of molecules such as prostaglandins, leukotrienes and thromboxanes: 
all these inflammatory mediators play a role in the pathophysiology of 
preterm birth [7]. The human body can produce the saturated and 
monounsaturated fatty acids but cannot synthesize omega-3 and 
omega-6 polyunsaturated fatty acids (PUFA). The precursors of these 
two families- alpha linolenic acid (ALA) and linoleic acid (LA)- are 
called “essential”; LA and ALA are required in the diet [3,4]. Foods 
with a higher content of omega- fatty acids include salmon, mackerel, 
sardines, herring, tuna, anchovies (blue fish). Dietary LA serves as the 
precursor for the n-6 series of polyunsaturated fatty acids (PUFAs) and 
dietary ALA is the precursor for the n-3 PUFA series. ALA is 
converted to eicosapentaenoic acid (EPA) and then in docosahexaenoic 
acid (DHA), while LA is converted to arachidonic acid (AA). DHA is 
an essential component of cell membranes, where it modulates, 
together with the EPA, the right degree of fluidity and permeability. 
The optimal omega-3/omega-6 fatty acids ratio is 1:5 whereas the 
western diet ranges from 10:1 to 25:1, fueling concern that this diet, 
characterized by low fish consumption, leads to a decline of omega-3 
PUFAs intake in favour of omega-6 PUFAs and to an altered omega-
6/omega-3 ratio from 1:10 to 1:20, a so called pro-inflammatory ratio. 
In fact, omega-3 fatty acids are essential and can only be obtained from 
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the diet [8]. The increased intake of omega-3 in proportion to other fats 
would 
result in the down-regulation of the synthesis of omega-6 and 
consequently the decreased production of pro-inflammatory cytokines 
[7]. The American Dietetic Association (ADA) with the Dietitians of 
Canada [2] recommend at least 500 mg/day of PUFAs for all healthy 
adults including pregnant and lactating women. The European 
Commission with the International Society for the Study of Fatty Acids 
and Lipids (ISSFAL) specifically recommends that pregnant and 
lactating women consume a minimum of 200 mg DHA per day [7,8]. 
These recommendations could be met by consuming 1 to 2 portions per 
week of fish with high content of omega-3 fatty acids, which is the 
recommendation by Health Canada [8] and the United States Dietary 
Guidelines Advisory Committee for all women [4]. Since this 
considerations we evaluate the role of docosahexaenoic acid on uterine 
contractions to show if this molecule can be of use in reducing the early 
symptoms and signs of preterm delivery.  
 
Materials and Methods 
We conducted a randomized double-blind controlled study by February 
2014 to November 2014. The study was conducted at the Reproductive 
Medicine Unit of the University of Naples Federico II. We enrolled 90 
symptomatic patients between 24-34 week of gestation, for threatened 
preterm labour. The study was approved by the Ethics Committee of 
the University Federico II (Protocol’s number 268/13). The patients 
underwent informed consent. The patients were divided into 2 groups 
according to random criteria, 45 patients in the treatment group (A 
group) and 45 to the placebo group (B group). 140 pregnant patients 
with pelvic pain at 24-34 weeks were evaluated. At the 
admission patients were submitted to digital vaginal examination, 
transvaginal ultrasonography and cardiotocography (CTG). Only 
patients with regular contractions at CTG (4 in 20 minutes or 8 in 60 
minutes, lasting at least 30 seconds) (1) and without clinical or 
sonographic modifications of the cervix were considered for the study. 
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The inclusion criteria were the following: 
1. Caucasian women between 18 and 38 years of age 
2. Singleton pregnancy 
3. Uterine contractions reported 
4. Regular uterine activity demonstrated to cardiotocography pattern (> 
4 contractions in 20 minutes) 
5. Cervical length > 25 mm and absence of funneling at transvaginal 
ultrasound 
6. Intact membranes 
7. Obstetric history negative for preterm labor. 
 
Patients with the following characteristics were excluded: 
1. Maternal age < 18 and > 38 
2. Multiple pregnancy 
3. Cervical length < 25 mm and / or presence of funneling at 
transvaginal ultrasound 
4. Infections of the genito-urinary tract (positive vaginal/urine culture) 
5. Intra-amniotic infections, based on clinical and biochemical 
parameters: maternal temperature > 38°C, malodorous vaginal 
discharge, maternal leucocytosis (>15000 cell/mm3), maternal 
tachycardia (>100 beats/min), uterine tenderness 
6. Pre-pregnancy or gestation pathologies (such as maternal 
autoimmune diseases, antiphospholipid syndrome, gestational 
hypertension, preeclampsia) 
Finally, 90 patients were enrolled in the study. Patients were randomly 
allocated in the 2 group, the treatment group (A group) and the placebo 
group (B group) using computer-generated numbers in sealed 
envelopes (Figure 1). The patients were randomized to receive a single 
vaginal capsule of docosahexaenoic acid (-Metra-medical device CE 
Class III produced by Pharmarte, registration number CE 0373 
containing fish oil rich in DHA - 1g) or vaginal placebo capsule. The 
placebo capsules were specially manufactured to look identical to the 
DHA capsules. The capsules were placed in sacs and then stored in 
envelopes numbered from 1 to 90. The envelopes were numbered and 
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randomized according to computer-generated randomization tables to 
ensure an equal number of patients in each arm. Access to the 
randomization code was available only to the pharmacist who 
manufactured the placebo and packed the envelops and was not 
available to any of the treating physicians or patients. Patients were 
revalued by cardiotocography pattern after 120 minutes after 
administration of the preparation. The primary endpoint was to 
determine the number of uterine 
contractions (<4 in 20 minutes or < 8 in 60 minutes) by tocography 
after 120 minutes from vaginal administration of one gram of DHA. 
 
Statistical analysis 
Statistical analysis was performed using Graph Pad Prism 4.0 software 
(Graph Pad Software Inc., La Jolla, CA). The t test was used for 
assessing the significance of the difference between continuous 
variables. The X2 test or the Fisher exact test was used to assess the 
statistical significance of categorical varables. Differences associated 
with p values lower than 0.05 were considered statistically significant. 
The results are reported as mean ± standard deviation (SD). A 
significant difference was found in terms of number of uterine 
contractions at CTG between the two groups (p< 0.05). 
 
Results 
In A group the mean number of contractions was significantly lower 
after the treatment (6.11±1.30 vs 3.13±3.33, p=0.0001) (Figure 2) while 
in B group the difference was not significant (5.28±1.32 vs 5.55±1.45, 
p=0.36) (Figure 3). Patients in A group showed a significant reduction 
in the mean number of contractions at cardiotocography after 120 
minutes of docosahexaenoic acid somministration than in B group 
(3.13±3.33 vs 5.55±1.45, p=0.0001) (Figure 4). The number of patients 
with a reduction of uterine contractions was significantly higher in A 
group. In particular, in A group, 20 patients (44%) had no contractions 
at the post-treatment CTG, 11 patients (24%) had a reduction in the 
number of contractions (< 6 in 60 minutes); in 9 patients (20%) the 
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number of contractions was unchanged and in 5 patients (11%) was 
detected worsening of symptoms. In B group, no patients showed 
improvement of symptoms, 28 patients (62%) presented an unchanged 
cardiotocographic pattern before and after the placebo, 15 patients 
(33%) showed worsening of the symptomatology and only 2 patients 
(5%) had a reduction in the number of contractions (Table 1). 
 
Discussion 
Variation of dietary intake plays a key role in reducing some risks 
associated with pregnancy, such as risk of fetal and infant mortality, 
low birth weight [12,13] and premature births [2]. In this study, we 
observed that vaginally administered DHA during pregnancy acts on 
uterine contractions, in symptomatic women resulting in muscle 
relaxation and induces disappearance of spontaneous contractions in 
many cases. Several randomized controlled trials have shown that 
supplementation 
with omega-3 may influence the birth process by delaying the onset of 
labor, reducing the risk of recurrent preterm birth and in animal studies 
it seems to have a tocolytic effect [2,15]. The exact DHA’s mechanisms 
of action are not well understood, the eicosanoid-mediated changes on 
myometrial contractions and the connective tissue remodeling [5,12,15] 
seem involved. A high omega-6/omega-3 fatty acid ratio will result in 
increasing proinflammatory eicosanoid production; these metabolites 
have been associated with labor at term and preterm. 
A higher intake of omega 3 fatty acids leads to a down-regulation of the 
synthesis of omega-6 fatty acids and consequently reduces the 
production of prostaglandins responsible for cervical changes in early 
labor. In additional, several studies have shown that DHA significantly 
reduces the secretion of IL-8 and IL-6 from the amnion [2,7]. These 
cytokines are strongly associated with the onset of labor and this 
activity may contribute to the ability of DHA, introduced by diet 
supplements, to prolong gestation and to decrease the risk of preterm 
delivery before 34 weeks. Animals with n-6 fatty acid deficiency and 
those fed with high dose of n-3 fatty acids have depressed 
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prostaglandins synthesis and increased length of gestation [8]. Another 
possible effect on the duration of pregnancy could be linked to the 
disorganization of the electrical myometrial activity: this could 
determine a delay in the onset of rhythmic and regular myometrial 
contractions [4]. Several randomized controlled trials showed a 
reduction of preterm delivery with DHA supplementation during 
pregnancy [6] n−3 supplementation was associated, compared to no 
supplementation in control subjects, with significantly greater duration 
of pregnancy [8]. The supplementation with marine 
oil in pregnancy is associated with a mean gestational age at delivery 
2.6 days longer than women allocated placebo or no treatment and did 
have a lower risk of giving birth before 34 completed weeks’ gestation 
compared with placebo [7]. Studies performed until today are based on 
the effects of oral administration of 200 mg omega-3 fatty acids, 
however, since oral administration is subject to hepatic metabolism and 
rapid inactivation, we hypothesized that the use of a vaginal 
formulation of DHA may provide a better bioavailability due to 
uterine-first-pass-effect, bypassing liver metabolism and directly 
reaching the cervix. Therefore, we evaluated the efficacy of 
intravaginal formulation of 1gr of DHA, which, in fact, resulted in a 
more effective activity on myometrium than the oral one. Avoiding the 
first-pass effect, vaginal administration could have a more potent 
cervical action, with a reduction of omega 6 synthesis and consequent 
lower production of PGE2 
and PGF2α.  
 
Conclusion 
Maternal long-chain polyunsaturated fatty acids status, particularly 
docosahexaenoic acid (DHA), during pregnancy may influence 
maternal and infant outcomes [2,13]. Maternal lifestyle and nutrition 
have long been recognized as important factors for both perinatal health 
and for the long-term health of the infant. Fish oil capsules are nearly 
devoid of mercury and other harmful compounds and can serve to 
augment omega-3 fatty acids in the diet. The implications of DHA 
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supplementation on fetal development, maternal outcomes and later 
infant growth is worth being elucidated and is promising in its potential 
for a positive impact on fetal and maternal outcomes [6]. 
The vaginal administration allows the use of dosage five times higher 
than the oral one, similar to the dosage tested in animal studies [3]. 
Furthermore, by passing the gastrointestinal absorption, DHA acts 
directly on the cervix and on the feto placental unit, contrasting 
hyperoxia [2]. Placental hyperoxia contributes to a persistent imbalance 
between pro-inflammatory and anti-inflammatory mechanisms that 
leads to preterm birth and neonatal injuries [17]. The potential benefits 
of DHA intake (1 gr) in patients at risk of preterm birth should be 
confirmed and further studies are needed to evaluate the effects and 
effectiveness of long-term treatment with DHA. 
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INTRODUCTION 
 
Preterm birth is the leading cause of perinatal and neonatal morbidity 
and mortality in developed countries contributing to 60-80% of all 
neonatal deaths. However, despite the intense work done by researchers 
in recent decades, the incidence of preterm birth remained virtually 
unchanged over the past 40 years. The etiology of preterm birth is 
multifactorial. Preterm birth would represent an uterine inflammatory 
response characterized by the production of prostaglandins by the 
amnion-chorion membranes and the decidua, with subsequent 
triggering uterine contractions and cervical modifications. α-lipoic acid 
(ALA) has antioxidant, as well as anti-inflammatory and 
immunomodulatory activity and presents no toxicity even at doses 
much higher than the therapeutic dose. The use of ALA in pregnancy is 
spreading due to its safety, tolerability and documented anti-
inflammatory action on the placenta. The vaginal administration of 
ALA is a new approach that can provide a direct effect on vaginal and 
uterine level, also in view of the low bioavailability after oral 
administration. 
 
METHODS 
The purpose of this study was to compare the therapeutic efficacy of 
ALA versus no treatment and versus progesterone (Pg) vaginally 
administered, in a selected group of patients with threatened preterm 
delivery after successful acute tocolytic therapy, considered for high 
risk due to cervical length < 20 mm. 125 patients were initially 
managed according to our clinical protocol after admission: 
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Prophylactic corticosteroid betamethasone i.m. 12 mg/day for 2 days 
and primary tocolysis (Atosiban or beta-mimetics for 48 hours). 
Patients who responded successfully to tocolytic therapy were still 
considered at high risk for cervicometry values < 20 mm. The patients 
were divided into three groups based on treatment modalities after 
primary tocolysis: group A (n = 43), vaginal Pg; Group B (n = 42), 
ALA; Group C (n = 40), no treatment. 
 
RESULTS 
We observed a reduction in preterm births (Group A = 23%, Group B = 
16% versus Group C = 50%), in recurrence of uterine contractile 
activity (Group A = 16%, Group B = 9% versus Group C = 32%), and 
in number of admissions to the Neonatal Intensive Care (Group A = 
18%, Group B = 14% versus Group C = 42%), in groups A and B. We 
found no differences between the group of patients treated with Pg and 
the group treated with ALA, except for a greater compliance to local 
therapy with ALA due to a lower frequency of adverse reactions (p < 
0.05). 
 
CONCLUSIONS 
The results of our study seem to support the role of progesterone as 
maintenance therapy, although in contrast to most of the scientific 
evidence. ALA appears to be a potential new treatment for the 
prevention of preterm delivery, allowing to prolong pregnancy in at risk 
patients, representing a valid alternative to progesterone. As its ability 
in reaching its site of action, the vaginal route seems to be favourite. 
ALA is safe, well tolerated, and vaginal administration has a good 
compliance and therefore it can be considered a viable integration to 
support tocolysis, even considering that maintenance therapy with 
progesterone is not supported. 
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The role of partosure™ test in predicting imminent 
preterm birth 
 E. Salzano, G. Nazzaro, M. Miranda, T. Palmieri, R. Iazzetta, M. Locci 
Journal of Pediatric and Neonatal Individualized Medicine 
2017;6(1):e060125 
 
INTRODUCTION 
An accurate risk assessment of preterm birth is clinically important in 
pregnancies with threatened preterm labor. This is particulary true with 
respect to both the administration of corticosteroids, as well as the 
transfer of patients to a tertiary care center capable of caring for the 
birth of premature infants. Clinical evaluation alone, with the 
measurement of cervical length and dilatation, are not sufficiently 
predictive of imminent delivery. Currently available biomarker tests, 
such as the detection of fetal fibronectin, have extramely poor 
predictive value form imminent delivery. The PartoSure™ test is a 
rapid, qualitative immunochromatographic test for the in vivo detection 
of placental alpha microglobulin-1 (PAMG-1) in vaginal secretions of 
pregnant women. PAMG-1 is a protein found in high concentrations in 
the amniotic fluid. 
 
METHODS 
We conducted a prospective observational study from March to June 
2016. We enrolled 20 symptomatic patients between 24-34 week of 
gestation with singleton pregnancy, irregular uterine activity and/or 
lower abdominal pain and pelvic pressure, intact membranes, cervical 
length < 20 mm and funneling. Patients were initially managed 
according to the internal protocol: prophylactic corticosteroid 
betamethasone i.m. 12 mg/day for 2 days and primary tocolysis for 48 
hours. 7 days after the therapy, we evaluated all the patients: 2 patients 
had delivered and 3 patients were excluded for premature rupture of 
membranes. In the final analysis, we included 15 patients. The 
PartoSure™ test was performed for these patients. The result was 
interpreted once two lines were visible, or after 5 min elapsed since the 
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insertion of the test strip into the sample vial. The patients were divided 
in two groups: the test was positive for two patients (Group A) and was 
negative for 13 patients (Group B). All patients had been revaluated 
after 7 and 14 days from the execution of the test. 
 
RESULTS 
In group A, a patient delivered within 7 days, while the others delivered 
within 14 days from presentation. In group B, a patient delivered within 
7 days, while 12 patients were still pregnant after 14 days. 
 
CONCLUSIONS 
In our study, the positive and negative predictive value of the 
PartoSure™ test seems to be high within 7 and 14 days (PPV 100%, 
NPV 92%). However, our conclusions are based on a small sample, so 
further studies are needed. If our results will be confirmed, the device 
could be considered an excellent test to rapidly assess the risk of 
preterm delivery within 7 or 14 days from time of collection of 
cervicovaginal sample in pregnant women with signs and symptoms of 
early preterm delivery, intact membranes and minimal expansion. A 
positive PartoSure™ test in these patients indicates with a high degree 
of accuracy that spontaneous preterm delivery will occur within 7 days. 
A negative result indicates that spontaneous preterm delivery within 14 
days is highly unlikely. 
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Future directions  
Epidemiological data show the association between neurological 
impairment and several factors such as preterm birth and intrauterine 
growth retardation. Unfortunately, these associations may not be simple 
and our understanding of biological mechanisms is often imperfect. 
However, several areas can be defined where intervention to prevent 
neurological injury could be valuable. 
Brains do not develop normally in the absence of critical genetic 
signaling and they do not develop normally in the absence of essential 
environmental input. At all levels of the neural system, progressive 
differentiation of specific elements and structures coupled with 
progressive commitment of those elements to functional systems 
appear to be the governing principles of brain development (47). 
The best chance of success will come from an integrated and multi-
disciplinary implementation strategy. This process begins with 
awareness across the medical and general communities that perinatal 
brain injury is one of modern health care’s greatest challenges, but that 
prevention in many cases is now possible. 
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